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ABSTRACT
The problem of microbial drug resistance is a major public health concern, due to its global dimension
and alarming magnitude, although the epidemiology of resistance can exhibit remarkable geographical
variability and rapid temporal evolution. The major resistance issues overall are those related to
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), Enterobac-
teriaceae producing extended-spectrum b-lactamases, and multidrug-resistant Pseudomonas aeruginosa
and Acinetobacter baumannii. Europe is not free from any of these issues, although their impact may be
signiﬁcantly different in different countries. MRSA rates are high in several European countries, but
seem to have levelled off in some settings. Diffusion of VRE is still irregular. The most alarming
resistance trends are those observed for Enterobacteriaceae and the Gram-negative non-fermenters, with a
generalized increase in rates of resistance to the most important anti-Gram-negative agents (b-lactams
and ﬂuoroquinolones) and the circulation of strains showing multidrug resistance phenotypes.
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THE PROBLEM: RESISTANT
PATHOGENS AT THE BEGINNING
OF THE NEW CENTURY
Microbial drug resistance has steadily evolved in
response to the selective pressure generated by
antimicrobial chemotherapy, and the introduction
of new antimicrobial agents has invariably been
followed by the appearance of resistant strains
among naturally susceptible bacterial species.
At the beginning of the new century, the
problem of microbial drug resistance has
achieved a global dimension and an alarming
magnitude, being one of the leading unresolved
problems in public health. The relentless evolu-
tion of resistance, in the face of a decrease in the
development of new antimicrobial agents active
against resistant pathogens, has led to an increas-
ing number of cases in which the pathogen is
resistant to most, or even all, drugs available for
clinical use (the so-called pandrug resistance
phenotypes), i.e. a situation reminiscent of the
pre-antibiotic era.
The epidemiology of drug resistance can
exhibit remarkable geographical variability and
rapid evolution over time, due to a complex
interplay of factors involved in the selection and
spread of different resistant ‘bugs’ and resistance
genes, which are still only partially understood.
The scope of this article is to brieﬂy analyse the
trends for major types of resistance in Europe,
including those related to methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resis-
tant enterococci (VRE), Enterobacteriaceae produc-
ing extended-spectrum b-lactamases (ESBLs), and
multidrug-resistant Pseudomonas aeruginosa and
Acinetobacter baumannii. Differences within other
settings and the potential impact on the selection
of empirical therapy are also discussed.
MRSA: DIFFERENT EVOLVING
TRENDS?
S. aureus remains one of the most important
pathogens, both in the hospital setting and in
the community [1], with MRSA being one of the
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most important resistant pathogens worldwide
[2]. The most recent data from the European
Antibiotic Resistance Surveillance System
(EARSS) conﬁrm the diffusion of MRSA in
Europe, but with notable variability in the pro-
portion of MRSA among invasive isolates from
different European countries (EARSS Annual
Report 2005 (2006); available at: http://www.
rivm.nl/earss/Images/EARSS%202005_tcm61-34
899.pdf (accessed 28 April 2007)). The highest
rates are reported in western and southern
Europe, and in the Balkan region, whereas rates
are lower in continental Europe, and even lower
in The Netherlands and in Scandinavia (Table 1).
Analysis of trends concerning the proportion of
MRSA observed in recent years (1999–2005)
revealed a signiﬁcantly increasing trend in some
countries, overall stability in others, and a signif-
icantly decreasing trend in two cases (France and
Slovenia, apparently after the enforcement of
strict control measures for MRSA) (Table 1).
In Europe, an overall stable trend in MRSA
rates has been reported for isolates from skin and
soft tissue infections (SSTIs) during the period
1998–2004 [3] (Fig. 1). Interestingly, this situation
was substantially different from that observed in
North America, where, during the same period, a
consistent increase in MRSA rates was observed
among isolates from SSTIs (Fig. 1). This phenom-
enon probably reﬂects the diffusion of MRSA at
the community level in the USA [1], due to the
emergence and spread of community-associated
MRSA strains (which are known to be mostly
responsible for SSTIs) and to the increasing
leakage from hospitals of the classical hospital-
associated MRSA strains. In Europe, the diffusion
of MRSA into the community has apparently been
delayed, although recent reports indicate that this
phenomenon is now emerging in several Euro-
pean countries [4; 17th European Congress of
Clinical Microbiology and Infectious Diseases,
2007; abstracts P1599, P1304 and P1324].
VRE: THE EUROPEAN SCENARIO
VRE, which are well-established resistant patho-
gens in the USA [5], remain a problem with an
overall lower and inconsistent impact in Europe.
In 2005, the proportion of VRE among invasive
isolates of Enterococcus faecium was higher than
30% in only four European countries (Greece,
Ireland, Portugal, and the UK) and in Israel,
whereas the proportion remained consistently
lower, or VRE were virtually absent, in others
(Table 1). An increasing trend was observed in
only some of the countries affected by the highest
rates (Table 1), but with a worrisome revival of
Table 1. Proportion (%) of methicillin-resistant Staphylo-
coccus aureus (MRSA) among invasive isolates of S. aureus
and of vancomycin-resistant enterococci (VRE) among
invasive isolates of Enterococcus faecium in several Euro-
pean countries in 2005
Country
S. aureus E. faecium
No. of
isolates % MRSA
No. of
isolates % VRE
Bulgaria 160 31 28 <1
Finland 790 3a 94 <1
France 3483 27b 194 2
Germany 874 21a 256 10a
Greece 681 42 227 37a
Italy 1431 37 193 19
Ireland 1360 42 220 31a
Israel 546 41 71 46a
The Netherlands 1401 <1a 188 <1
Poland 197 24 20 5
Portugal 1153 47a 95 34b
Romania 83 61a 10 <1
Slovenia 349 10b 30 <1
Spain 1337 27 141 3
Sweden 1774 1 253 <1
UK 3967 44a 224 33
Data are from the EARSS 2005 annual report (EARSS Annual Report 2005 (2006), pp.
143–144; available at: http://www.rivm.nl/earss/Images/EARSS%202005_tcm61-
34899.pdf (accessed 28 April 2007)).
aSigniﬁcant increasing trend observed during recent years.
bSigniﬁcant decreasing trend observed during recent years.
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Fig. 1. Proportion (%) of methicillin-resistant Staphylo-
coccus aureus (MRSA) among S. aureus isolates from skin
and soft tissue infections in Europe and in North America
during the period 1998–2004. Data are from Moet et al.[3].
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vancomycin-resistant E. faecium, recently reported
in England and Wales (available at: http://
www.hpa.org.uk/web/HPAwebFile/HPAweb_
C/1224142369573 (accessed 28 October 2008)).
The proportion of vancomycin-resistant strains
remains much lower among Enterococcus faecalis,
the enterococcal species most commonly isolated
from clinical sources, with rates that have attained
a maximum of 5% (in Portugal), but are lower
than 1% in most countries (EARSS Annual Report
2005 (2006), pp. 49–51; available at: http://www.
rivm.nl/earss/Images/EARSS%202005_tcm61-34
899.pdf (accessed 28 April 2007)).
ESBL PRODUCTION AND
MULTIDRUG RESISTANCE IN
ENTEROBACTERIACEAE : A RAPIDLY
CHANGING EPIDEMIOLOGY
The emergence and dissemination of ESBL pro-
ducers among the Enterobacteriaceae dates back to
the mid-1980s, and is a consequence of the
selective pressure generated by the introduction
of oxyimino-cephalosporins into clinical practice.
The evolution of ESBLs in Enterobacteriaceae has
occurred through two major mechanisms: (i)
selection for point mutants of the TEM- and
SHV-type plasmid-mediated broad-spectrum
b-lactamases (prevalent among Enterobacteriaceae
circulating in the clinical setting since the 1970s),
which have acquired the ability to degrade
expanded-spectrum cephalosporins and mono-
bactams; and (ii) capture of new ESBL genes from
environmental bacteria (e.g. the genes encoding
CTX-M-, VEB-, GES-, TLA-, SFO- and BES-type
enzymes) through horizontal gene transfer [6].
Recent international surveillance data indicate
an overall increasing trend in ESBL production
rates in Europe, not only in Klebsiella pneumoniae
(the species in which ESBLs are most wide-
spread), but also in Escherichia coli [7]. In Europe,
an increasing trend in ESBL production in E. coli
has also been reported for isolates causing SSTIs
[3]. These data are consistent with the reported
increasing trends concerning resistance to third-
generation cephalosporins (3GCs) in E. coli (which
largely reﬂect ESBL production) in most Euro-
pean countries (EARSS Annual Report 2005
(2006); available at: http://www.rivm.nl/earss/
Images/EARSS%202005_tcm61-34899.pdf (accessed
28 April 2007)) (Table 2), and in England and
Wales (recent HPA surveillance data; available
at: http://www.hpa.org.uk/infections/topics_az/
ecoli/ecoli07/amr.htm (accessed 28 April 2007)).
The explosive diffusion of ESBL-producing E. coli
strains, which are no longer restricted to the
hospital setting but are also spreading within the
community [8], is clearly a matter of serious
concern that may have major implications for
empirical therapy, as E. coli is the most common
Gram-negative species isolated from clinical spec-
imens in either setting [1].
The mechanisms underlying this recent epide-
miological evolution are not fully understood;
they seem, at least in part, to be related to the
emergence and dissemination of the CTX-M-type
ESBL genes. These genes, captured from Kluyvera
spp., are carried on transferable plasmids that
exhibit a notable propensity to spread among
E. coli and other Enterobacteriaceae [9,10], and their
acquisition can generate highly successful clones
[11,12]. Indeed, rapid dissemination of CTX-M-
type ESBLs has recently been documented in
several European countries, where these enzymes
are becoming the dominant type of ESBL and
have outnumbered the classical TEM- and SHV-
type ESBL variants [13]. ESBL production is a
matter of clinical concern, not only because it
impairs the activity of expanded-spectrum ceph-
alosporins and most other b-lactams (except
carbapenems), but also because it is often linked
to multidrug resistance (MDR) concerning other
anti-Gram-negative agents (e.g. aminoglycosides
Table 2. Rates (%) of resistance to third-generation
cephalosporins (3GCs) and of multidrug resistance
(MDR) among invasive isolates of Escherichia coli in
different European countries
Country
3GC MDR
No. of
isolates
Resistance
rate (%)
No. of
isolates
Resistance
rate (%)
Bulgaria 203 28a 196 16
France 5835 1a 5808 0
Germany 1012 2a 1006 0
Greece 1139 7 1136 2
Italy 1191 8a 1090 4
The Netherlands 1890 2a 1182 1
Poland 176 5 175 3
Portugal 1076 12a 1039 8
Romania 80 16 75 3
Spain 2997 8a 2992 3
Sweden 3198 1a 2991 0
UK 1692 6a 1689 2
Data are from the EARSS 2005 annual report (EARSS Annual Report 2005 (2006), p.
145; available at: http://www.rivm.nl/earss/Images/EARSS%202005_tcm61-348
99.pdf (accessed 28 April 2007)). MDR was deﬁned as resistance to ﬂuoroquinol-
ones, 3GCs and aminoglycosides, irrespective of susceptibility to aminopenicillins.
aSigniﬁcant increasing trend observed during recent years.
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and ﬂuoroquinolones) [14]. Indeed, a worrisome
and increasing trend in MDR (deﬁned as resis-
tance to ﬂuoroquinolones, 3GCs, and aminogly-
cosides) has been reported for E. coli in many
European countries (EARSS Annual Report 2005
(2006); available at: http://www.rivm.nl/earss/
Images/EARSS%202005_tcm61-34899.pdf (accessed
28 April 2007)) (Table 2).
Carbapenems are the only b-lactams that retain
potent activity against multidrug-resistant Entero-
bacteriaceae producing ESBLs, and clinical data
indicate that they are the drugs of choice for the
treatment of serious infections caused by similar
strains [14,15]. Acquired carbapenem resistance,
however, can emerge among Enterobacteriaceae
through at least two different mechanisms: (i)
loss of porins in strains of Klebsiella spp. produc-
ing ESBLs or in strains of Enterobacter spp.
overproducing AmpC-type b-lactamases; or (ii)
production of an acquired carbapenemase [16].
The former mechanism involves mutation, and
can emerge during carbapenem therapy [17]. A
recent report from the UK suggests that Klebsiella
and Enterobacter isolates with this resistance
mechanism are increasing in frequency [18].
Concerning acquired carbapenemases, with
very few exceptions the enzymes found in
Enterobacteriaceae are either serine carbapene-
mases of molecular class A (e.g. KPC-, SME- and
NMC ⁄ IMI-type enzymes) or metallo-b-lactamases
(MBLs) of molecular class B (e.g. IMP- and VIM-
type enzymes) [16,19]. The class A serine
b-lactamases (especially the KPC-type enzymes)
are currently emerging on the east coast of the
USA [20], and do not yet appear to have had a
signiﬁcant impact in Europe, although a recent
report describing a multiclonal outbreak of KPC-
producing E. coli in Israel [21] could be a harbin-
ger of the emergence of these enzymes in Europe
and in the Mediterranean region. Acquired MBLs
are still uncommon among Enterobacteriaceae
[20,22,23], except in Greece, where a remarkable
spread of acquired MBLs has recently been
observed among Enterobacteriaceae [24–27], and
this is apparently the major cause of the unusually
high rates of carbapenem resistance (27.8% in
2005 and 27.9% in 2006) reported by the EARSS
surveillance system among invasive isolates of
K. pneumoniae from Greece (http://www.earss.-
rivm.nl). MBL-producing strains can exhibit very
complex MDR phenotypes, due to the acquisition
of multiple resistance determinants. Indeed,
K. pneumoniae strains producing the VIM-1 MBL
and the SHV-5 ESBL, showing a virtually pan-
drug-resistant phenotype, have recently been
described in intensive-care units (ICUs) of Greek
hospitals [28].
P. AERUGINOSA AND A. BAUMANNII :
TOWARDS COMPLEX MULTIDRUG
AND PANDRUG RESISTANCE
Antibiotic resistance is even more serious among
the Gram-negative non-fermenters (GNNFs)
P. aeruginosa and A. baumannii, which are impor-
tant nosocomial pathogens, especially in ICUs.
The EARSS surveillance data, which have been
extended to include P. aeruginosa since 2005,
reveal that acquired resistance to major anti-
pseudomonal agents is a sizeable problem in
several countries, although with remarkable geo-
graphical differences (EARSS Annual Report 2005
(2006), pp. 66–71; available at: http://www.
rivm.nl/earss/Images/EARSS%202005_tcm61-34
899.pdf (accessed 28 April 2007). Overall, the most
serious problems are encountered in the countries
of eastern Europe, with rates of resistance to
piperacillin, ceftazidime, carbapenems, ﬂuoroqui-
nolones and aminoglycosides that in some cases
(e.g. Romania) can exceed 50% (Table 3).
P. aeruginosa can acquire resistance to any
antipseudomonal drug through a broad reper-
toire of resistance mechanisms, and exhibits a
remarkable propensity to acquire MDR pheno-
types [29–31]. Overall, 7.4% of invasive P. aeru-
ginosa isolates from Europe were found to be
resistant to the ﬁve classes of drugs (piperacillin
and tazobactam, 3GCs, carbapenems, aminogly-
cosides, and ﬂuoroquinolones) surveyed by the
EARSS in 2005 (EARSS Annual Report 2005
(2006), pp. 70; available at: http://www.
rivm.nl/earss/Images/EARSS%202005_tcm61-34
899.pdf (accessed 28 April 2007)), whereas the
isolation of strains resistant to most or all the
available antipseudomonal drugs, except colistin,
is no longer exceptional and is highly alarming in
the clinical setting [32,33].
Concerning Acinetobacter spp., the most recent
European data from the SENTRY surveillance
system (referring to the period 2001–2004) re-
vealed that, except for colistin, which was active
against 97.3% of isolates, only carbapenems
retained substantial activity (rates of susceptibil-
ity to imipenem and meropenem were 73.7% and
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70.4%, respectively). For other b-lactams (ceftaz-
idime and cefepime) and ciproﬂoxacin, the sus-
ceptibility rates were lower than 50% [34]. Data
for Acinetobacter spp. isolates from ICUs in North
America and in some European countries (France,
Germany, and Italy), reported by The Surveillance
Network Database (Focus Technologies, Inc.,
Herndon, VA), referring to the years 2000–2002,
are consistent with the ﬁnding that carbapenems
are the only anti-Acinetobacter drugs that retain
substantial activity [35] (Table 4). These data also
revealed remarkable geographical variability in
the susceptibility to various drugs (Table 4),
which is probably related to the dissemination
of Acinetobacter clones with different resistance
phenotypes in different settings [36].
Under these circumstances, the dissemination
of multidrug-resistant Acinetobacter clones that
have also acquired resistance to carbapenems is a
most worrisome aspect of the evolution of micro-
bial drug resistance [37]. A recent paradigmatic
example of this phenomenon has been observed
in England, where a carbapenem-resistant A. bau-
mannii clone that produces the OXA-23 carbape-
nemase and is susceptible only to colistin and
tigecycline has started spreading in London and
Southeast England [38]. In fact, acinetobacters
have evolved several mechanisms to acquire
carbapenem resistance; the acquisition of OXA-
type carbapenemases, e.g. OXA-23, OXA-24, and
OXA-58, appears to be one of the most important
emerging mechanisms [39].
CONCLUDING REMARKS
Antibiotic resistance issues concerning all major
nosocomial pathogens exist in the European
setting, although with signiﬁcantly different im-
pacts in different countries.
With regard to Gram-positive pathogens,
MRSA rates are high overall in many European
countries, but seem to have levelled off in some
settings, whereas VRE diffusion is still irregular,
with an important and growing impact in some
countries but not in others.
On the other hand, remarkable increasing
trends in resistance of Enterobacteriaceae and
GNNFs have recently been observed in most
European countries. In Enterobacteriaceae, the
major problems are: (i) increasing resistance to
expanded-spectrum cephalosporins (mostly med-
iated by ESBL production) and ﬂuoroquinolones;
(ii) increasing prevalence of strains with MDR
phenotypes; (iii) and progressive extension of the
Table 3. Rates (%) of resistance to
various antipseudomonal agents
among invasive isolates of Pseudo-
monas aeruginosa from different
European countries
Country Piperacillin Ceftazidime Carbapenems Fluoroquinolones Aminoglycosides
Bulgaria 50 45 38 47 53
France 15 9 14 27 22
Germany 17 11 24 19 13
Greece 30 27 39 39 40
Ireland 7 10 11 14 7
The Netherlands 4 5 5 9 7
Poland 50 31 27 31 56
Romania 61 52 61 64 64
Spain 4 6 17 14 4
Sweden 9 5 18 6 <1
UK 2 3 9 8 3
Data are from the 2005 EARSS report (EARSS Annual Report 2005 (2006), p. 147; available at: http://www.rivm.nl/
earss/Images/EARSS%202005_tcm61-34899.pdf (accessed 28 April 2007)).
Table 4. Rates (%) of susceptibil-
ity among intensive-care unit iso-
lates of Acinetobacter spp. from
France, Germany, Italy and North
America during the period 2000–
2002
Antimicrobial agent
Susceptibility rates (%) in:
USA Canada France Germany Italy
Cefepime 44 67 28 74 18
Cefotaxime 23 37 15 35 11
Ceftazidime 42 71 35 67 26
Ciproﬂoxacin 40 72 38 75 21
Gentamicin 47 73 49 82 23
Imipenem 87 96 94 96 78
Levoﬂoxacin 44 61 NR 82 14
Meropenem 66 94 68 96 75
Piperacillin–tazobactam 54 71 75 82 35
Data are from Jones et al. [35].
NR, not reported.
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corresponding resistance determinants and the
associated clinical problems to E. coli. Carbapen-
ems retain overall potent activity against multi-
drug-resistant enterobacteriaceae, but acquired
carbapenem resistance has been reported in some
settings and can be mediated by several mecha-
nisms. In GNNFs, resistance to major anti-Gram-
negative agents tends to be even more serious and
prevalent, with complex MDR phenotypes
increasing in frequency, and pandrug resistance
phenotypes no longer being an exceptional
ﬁnding.
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